JPRN-UMIN000015230已完成未知
Open-label, randomized, controlled study evaluating dose-escalation of peginterferon alpa-2b plus ribavirin in aged patients with chronic hepatitis C - Randomized study evaluating dose-escalation of combination therapy in aged patients with chronic hepatitis C
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 60years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Hemoglobin values at entry visit less than 12 g/dL. 2. Allergic to interferon or vaccine preparations. 3. Allergic to ribavirin or other nucleos(t)ide preparations. 4. Pregnant or under breast feeding. 5. Uncontrolled cardiovascular diseases. 6. Abnormal hemoglobinemia. 7. Chronic renal failure or creatinine clearance value less than 50 mL/min. 8. Neurologic or psychiatric disease. 9. Sever or decompensated liver disease. 10. Hypertension or diabetes. 11. History of apoplexy. 12. Autoimmune hepatitis. 13. Chronic hepatitis B or excessive daily intake of alcohol 14. Concomitant immunosuppressive or herbal medication such as Sho-saiko-to. 15. Other conditions considered inappropriate by attending physician.
研究者
相似试验
招募中
4 期
The efficacy of angiotensin receptor neprilysin inhibitor in patients after transcatheter aortic valve implantation.Aortic stenosisJPRN-jRCT1031220344Kitahara Hideki84
招募中
2 期
An open-label, randomized controlled study evaluating the effectiveness of Pramipexole extended-release tablets for tardive dystonia patientsTardive dystoniaDrug-induced extrapyramidal syndromeG240JPRN-jRCTs031180316Iyo Masaomi24
招募中
2 期
An open-label, randomized controlled study evaluating the effectiveness of pramipexole extended-release tablets for tardive dystonia.Tardive dystoniaJPRN-UMIN000014988Department of Psychiatry, Chiba University Graduate School of Medicine24
尚未招募
4 期
Evaluate Partial Meal Replacement with Prohance D (Nutraceutical Product) in type II Diabetic PopulatioCTRI/2019/10/021595Sun Pharma Industries limited
进行中（未招募）
不适用
A Randomized, Controlled, Open- label Study Evaluating the Efficacy and Tolerability of AMG 531 versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects with Immune (Idiopathic) Thrombocytopenic PurpuraEUCTR2006-003700-18-ATAmgen Inc.210